Pharmacyclics, Inc.

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of Pharmacyclics, Inc. (NASDAQ GS: PCYC) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Pharmacyclics, Inc. (“Pharmacyclics” or the “Company”) (NASDAQ GS: PCYC) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by AbbVie Inc. (“AbbVie”) (NYSE: ABBV), in a transaction valued at approximately $21 billion.

Under the terms of the agreement, shareholders of Pharmacyclics will receive $261.25 per share, consisting of cash and AbbVie common stock.  Pharmacyclics’ stockholders will be permitted to elect cash, AbbVie common stock or a combination, subject to proration.  The aggregate consideration will consist of approximately 58% cash and 42% AbbVie common stock.

The investigation concerns whether Pharmacyclics’ board of directors failed to adequately shop the Company and obtain the best possible value for Pharmacyclics’ shareholders before entering into an agreement with AbbVie.

If you own the common stock of Pharmacyclics and purchased your shares before March 5, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.